[pick list]
[Hi]
[Hello]
[Greetings]
[pick list]
[First Name]
[First Name Last Name]
[Dr. Last Name]
,
|
|
Thank you for your interest in Elfabrio— a category-unique PEGylated ERT for Fabry disease— purposefully designed for long-lasting results.1-3
|
|
|
[email fragments]
|
[FRAGMENT 1]
|
|
• Long-lasting ERT (PEGylation, 80hr half-life)
|
|
|
[FRAGMENT 2]
|
|
• Infusion Experience (no need for premedication, dosing at home or in the clinic in as little as 90 minutes)
|
|
|
[FRAGMENT 3]
|
|
• Efficacy (main endpoints & QOL) & Safety (low risk of immunogenicity, years of study, common side effects)
|
|
|
[FRAGMENT 4]
|
|
|
|
[Elfabrio_Half-Life]
|
|
Get more information on the lasting impact of an 80-hour half-life.
|
|
|
[Elfabrio_Renal and Cardiac stability]
|
|
Review disease progression efficacy data.
|
|
|
[Elfabrio_Efficacy and Safety]
|
|
Review clinical efficacy and safty data for Elfabrio.
|
|
|
[Elfabrio_Total Care]
|
|
Find out how the Chiesi Total CareSM patient support team can help the transition to Elfabrio.
|
|
|
Elfabrio is an exciting option for patients being treated for Fabry disease, and the thousands of people with Fabry who may remain untreated—even though they could benefit from therapy.X
Picture what Elfabrio can do for your patients with Fabry disease:
|
 |
Category-unique
PEGylated ERT
purposefully
designed for
long-lasting results1-3
|
Infusions in
as little as
90 minutes—
in the clinic or
at home1,Y
|
Sustained
efficacy that
reduced key
markers of
diseease1
|
|
Your patients will also have access to Chiesi Total CareSM to help create a seamless transition to Elfabrio—including support for home infusions.
As with any new treatment, there is a lot of new data and information. You, your staff, patients and caregivers will undoubtedly have quetions from time to time. I'd be happy to set up a
[pick list]
[
falsecall
truevideo chat
truemeeting
]
to discuss any questions you may have about Elfabrio. Simply respond to this email or call me at [phone] to schedule the discussion.
|
|
|
[email fragments]
|
[FRAGMENT 1]
|
|
• Long-lasting ERT (PEGylation, 80hr half-life)
|
|
|
[FRAGMENT 2]
|
|
• Infusion Experience (no need for premedication, dosing at home or in the clinic in as little as 90 minutes)
|
|
|
[FRAGMENT 3]
|
|
• Efficacy (main endpoints & QOL) & Safety (low risk of immunogenicity, years of study, common side effects)
|
|
|
[FRAGMENT 4]
|
|
|
|
[Elfabrio_Half-Life]
|
|
Get more information on the lasting impact of an 80-hour half-life.
|
|
|
[Elfabrio_Renal and Cardiac stability]
|
|
Review disease progression efficacy data.
|
|
|
[Elfabrio_Efficacy and Safety]
|
|
Review clinical efficacy and safty data for Elfabrio.
|
|
|
[Elfabrio_Total Care]
|
|
Find out how the Chiesi Total CareSM patient support team can help the transition to Elfabrio.
|
|
|
[pick list]
[Sincerely]
[Best regards]
[look forward to discussion with you]
[Thank you]
,
|
|
[Rep photo]
|
[Rep Name]
[Rep Title]
[Rep Phone Number]
[Rep E-mail]
|
|
ERT, enzyme replacement therapy.
[References per each option will go here]Lorem ipsum dolor sit amet, consectetuer adipiscing elit, sed diam
nonummy nibh euismod tincidunt ut laoreet dolore magna aliquam erat volutpat. Ut wisi enim ad minim veniam,
quis nostrud exerci tation ullamcorper suscipit lobortis nisl ut aliquip ex ea commodo consequat. Duis autem vel
eum iriure dolor in hendrerit in vulputate velit esse molestie consequat, vel illum dolore eu feugiat nulla facilisis
at vero eros et accumsan et iusto odio dignissim qui blandit praesent luptatum zzril delenit augue duis dolore te
feugait nulla facilisi.
|
INDICATION
Lectus arcu bibendum at varius vel pharetra vel. Ultrices in iaculis nunc sed. Malesuada
fames ac turpis egestas sed tempus. Neque ornare aenean euismod elementum. Nisl
nunc mi ipsum faucibus vitae aliquet nec ullamcorper. Felis eget velit aliquet sagittis id.
Eget nunc scelerisque viverra mauris in.
|
IMPORTANT SAFETY INFORMATION
Lectus arcu bibendum at varius vel pharetra vel. Ultrices in iaculis nunc sed. Malesuada
fames ac turpis egestas sed tempus. Neque ornare aenean euismod elementum. Nisl
nunc mi ipsum faucibus vitae aliquet nec ullamcorper. Felis eget velit aliquet sagittis id.
Eget nunc scelerisque viverra mauris in. Lectus arcu bibendum at varius vel pharetra vel. Ultrices in iaculis nunc sed. Malesuada
fames ac turpis egestas sed tempus. Neque ornare aenean euismod elementum. Nisl
nunc mi ipsum faucibus vitae aliquet nec ullamcorper. Felis eget velit aliquet sagittis id.
Eget nunc scelerisque viverra mauris in.
|
For Full Prescribing Information, please click here.
|
